149 COMMONWEALTH DRIVE, MENLO PARK, CA
Earnings Release
Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Other Events
Stockholders Approve Amendment to 2024 Incentive Award Plan
Financial Results, Reg. FD
FDA Approves Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Provides Update on Patent Dispute with Teva Pharmaceuticals
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
S-8 POS